In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Amgen and Biovitrum sign license agreements

20 Jan 2017

Executive Summary

To strengthen its foothold in the area of metabolic diseases, Amgen licensed exclusive development and marketing rights in North and South America, the EU, Australia, and New Zealand to Biovitrum AB's (focuses on metabolic disorders) small-molecule 11beta-hydroxysteroid dehydrogenase 1 (HSD1) enzyme inhibitor platform. It will initially concentrate on developing BVT.3498, which is in Phase IIa clinical trials to treat Type II diabetes and related metabolic diseases. The deal also gives Biovitrum rights to some Amgen products.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Intra-Biotech Deal
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

;